BR112018001980A2 - compostos cíclicos úteis como moduladores de tnf alfa - Google Patents

compostos cíclicos úteis como moduladores de tnf alfa

Info

Publication number
BR112018001980A2
BR112018001980A2 BR112018001980A BR112018001980A BR112018001980A2 BR 112018001980 A2 BR112018001980 A2 BR 112018001980A2 BR 112018001980 A BR112018001980 A BR 112018001980A BR 112018001980 A BR112018001980 A BR 112018001980A BR 112018001980 A2 BR112018001980 A2 BR 112018001980A2
Authority
BR
Brazil
Prior art keywords
compounds useful
cyclic compounds
compounds
alpha tnf
modulators
Prior art date
Application number
BR112018001980A
Other languages
English (en)
Portuguese (pt)
Inventor
Jiang Bin
Xiao Hai-Yun
Duan Jingwu
G Murali Dhar T
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112018001980A2 publication Critical patent/BR112018001980A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112018001980A 2015-08-03 2016-08-02 compostos cíclicos úteis como moduladores de tnf alfa BR112018001980A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200415P 2015-08-03 2015-08-03
PCT/US2016/045104 WO2017023902A1 (en) 2015-08-03 2016-08-02 Cyclic compounds useful as modulators of tnf alpha

Publications (1)

Publication Number Publication Date
BR112018001980A2 true BR112018001980A2 (pt) 2018-09-18

Family

ID=56610045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001980A BR112018001980A2 (pt) 2015-08-03 2016-08-02 compostos cíclicos úteis como moduladores de tnf alfa

Country Status (13)

Country Link
US (1) US10335392B2 (https=)
EP (1) EP3331889B1 (https=)
JP (1) JP6811233B2 (https=)
KR (1) KR102679517B1 (https=)
CN (1) CN108137609B (https=)
AU (1) AU2016301215A1 (https=)
BR (1) BR112018001980A2 (https=)
CA (1) CA2994703A1 (https=)
EA (1) EA201890421A1 (https=)
ES (1) ES2828696T3 (https=)
IL (1) IL257159A (https=)
MX (1) MX2018001173A (https=)
WO (1) WO2017023902A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288939A1 (en) 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
EP4556478A4 (en) * 2022-08-08 2025-10-22 Medinno Pharmaceutical Tech Zhuhai Co Ltd TGF-BETA INHIBITOR COMPOUND AND USE THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5149386A (ja) * 1974-10-28 1976-04-28 Hitachi Ltd Shuchukanshiseigyohoho
CA2281927C (en) 1997-02-25 2004-01-27 Christopher J. Michejda Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ[1,2−a]ピリジン誘導体
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
CN103739605B (zh) 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
KR101669334B1 (ko) * 2013-09-30 2016-10-25 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf

Also Published As

Publication number Publication date
EP3331889A1 (en) 2018-06-13
ES2828696T3 (es) 2021-05-27
JP6811233B2 (ja) 2021-01-13
IL257159A (en) 2018-03-29
US10335392B2 (en) 2019-07-02
WO2017023902A1 (en) 2017-02-09
KR20180031773A (ko) 2018-03-28
US20180221344A1 (en) 2018-08-09
KR102679517B1 (ko) 2024-06-27
MX2018001173A (es) 2018-04-24
CN108137609A (zh) 2018-06-08
CA2994703A1 (en) 2017-02-09
EP3331889B1 (en) 2020-09-23
EA201890421A1 (ru) 2018-07-31
JP2018525377A (ja) 2018-09-06
CN108137609B (zh) 2021-07-16
AU2016301215A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
BR112018001980A2 (pt) compostos cíclicos úteis como moduladores de tnf alfa
BR112018001960A2 (pt) compostos heterocíclicos úteis como moduladores de tnf alfa
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2017016995A (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MD4516C1 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
BR112017019731A2 (pt) compostos heterocíclicos tricíclicos úteis como inibidores de tnf
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
BR112017019773A2 (pt) compostos heterocíclicos tricíclicos substituídos
BR112017019605A2 (pt) compostos heterocíclicos úteis como inibidores de tnf
MX374728B (es) MODULADORES DE ROR GAMMA (RORy).
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112015015654A2 (pt) monômeros fluorescentes e polímeros de tratamento marcados contendo os mesmos para o uso em sistemas de água industriais
CR20160030A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2015002897A1 (es) Inhibidores de bace1
BR112015013485A2 (pt) derivados de benzilsulfonamida como moduladores de rorc
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
CR20170035A (es) Compuestos de imidazopiridazina
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]